Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Relapse after HSCT 2021 | The use of viral-specific T-cells post bone marrow transplantation

Susan Prockop • 5 Oct 2021
Relapse after HSCT 2021
General Lymphoma

Susan Prockop, MD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on the use of viral-specific T-cells (VSTs) following bone marrow transplantation (BMT). In comparison to other cellular therapies, VSTs have minimal toxicity and do not induce high rates of graft-versus-host disease (GvHD). Dr Prockop introduces the data that she is going to present at R-HSCT², which includes clinical trials demonstrating the efficacy of third-party VSTs in patients with Epstein-Barr virus (EBV)-associated lymphoid malignancies. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.

More from Susan Prockop

1:12
The contribution of viral infections, such as EBV, to post-transplant lymphoproliferative disease
Susan Prockop • 16 Apr 2024
2:21
Tab-cel for solid organ or allogeneic transplant recipients with EBV-PTLD
Susan Prockop • 23 Apr 2022
1:56
Strategies for the management of EBV-PTLD
Susan Prockop • 23 Apr 2022
1:29
Improving virus-specific T-cell therapy
Susan Prockop • 5 Oct 2021

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals